University of Pittsburgh and Carnegie Mellon University researchers have developed a novel molecule, CPM3-gPNA, designed to treat mitochondrial DNA (mtDNA) heteroplasmy. This molecule targets and blocks the replication of the m.3243A>G mtDNA mutation, which is associated with diseases such as Maternally Inherited Diabetes and Deafness (MIDD) and Myoclonic Encephalopathy, Lactic Acidosis, with or without Seizures (MELAS). By reducing the mutation load below the critical threshold, CPM3-gPNA has the potential to alleviate symptoms and improve patient outcomes.